FERRING PHARMACEUTICALS A/S: Financial statements 2024
CVR: 16313440
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
FERRING PHARMACEUTICALS A/S (CVR 16313440) has filed annual accounts for 2024. In 2024, the company reported revenue of DKK 1,690,294,000 and a net result of DKK 76,890,000 compared with DKK 67,110,000 the year before. That is an increase of 16% compared with the year before. The profit margin was 4.5%. Equity in the 2024 report amounted to DKK 266,214,000. The solvency ratio was 48%. The company had 487 employees in the financial year.
- Revenue
- DKK 1,690,294,000
- Gross Profit
- DKK 811,057,000
- Profit/Loss
- DKK 76,890,000
- Equity
- DKK 266,214,000
- Total Assets
- DKK 554,485,000
- Employees
- 487
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 1.7B | 811.1M | 76.9M | 266.2M | 487 |
| 2023 | 1.5B | 707.8M | 67.1M | 189.3M | 497 |
| 2022 | 1.3B | 645.9M | 52.4M | 122M | 559 |
| 2021 | 1B | 1B | 40.2M | 69.6M | 487 |
| 2020 | 1.1B | 1.1B | 40.9M | 79.4M | 497 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
FERRING PHARMACEUTICALS A/S has published its annual report for 2023. Revenue came to DKK 1,457,509,000, and the net result was DKK 67,110,000.
As of March 1, 2024, Pierre Yves Berclaz has joined the board of directors of FERRING PHARMACEUTICALS A/S.
As of March 1, 2024, Jean-Frederic Paulsen has joined the board of directors of FERRING PHARMACEUTICALS A/S.
As of March 1, 2024, Armin Metzger has left the board of directors of FERRING PHARMACEUTICALS A/S.
As of March 1, 2024, Anette Hedegaard Østergaard is registered as director of FERRING PHARMACEUTICALS A/S.
As of February 1, 2024, Marianne Kock has joined the board of directors of FERRING PHARMACEUTICALS A/S.
As of February 1, 2024, Per Gunnar Falk has left the board of directors of FERRING PHARMACEUTICALS A/S.
As of February 1, 2024, Jan Peutzfeldt is registered as adm. dir. of FERRING PHARMACEUTICALS A/S.
As of February 1, 2024, Marianne Kock has stepped down as adm. dir. of FERRING PHARMACEUTICALS A/S.
As of January 31, 2024, Marianne Kock has left the board of directors of FERRING PHARMACEUTICALS A/S.
About FERRING PHARMACEUTICALS A/S
FERRING PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Kastrup, founded in 1992. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named FERRING NORDIC PHARMACEUTICALS A/S and A/S PSE 38 NR. 1587. The management consists of Jan Peutzfeldt, Ingbritt Tolstrup Birk and Jesper Thomsen. The board consists of Marianne Kock (chair), Dag Frederik Arfst Paulsen and Jean-Frederic Paulsen. The company is owned by Ferring B.V.. The company has 522 employees (2026). In 2025, the company reported revenue of DKK 1,730,413,000 and a net result of DKK 49,005,000 compared with DKK 76,890,000 the year before. Equity in the 2025 report amounted to DKK 315,220,000.